CClinicalTrials.gg
Active, not recruitingNCT06704737Updated Nov 26, 2024

AR Training in Adults With Unilateral Amblyopia

An interventional study of AR training and Patching in Amblyopia Unilateral and Amblyopia Functional, sponsored by Eye & ENT Hospital of Fudan University. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-11-26.

Sponsored by Eye & ENT Hospital of Fudan University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 9 months ago, but the record still lists the study as active, not recruiting.
  • Registered 1 year 8 months after the study started (first participant enrolled Feb 2023, registered Nov 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This is a single-center, non-randomized controlled trial to compare the effectiveness of binocular AR training with patching for the treatment of adults with unilateral amblyopia.

Specific Aim 1 (Primary): To compare the improvement of visual acuity in the amblyopic eye between AR training and patching for the treatment of adults with unilateral amblyopia.

Specific Aim 2 (Secondary): To compare the changes of visual functions and pathway selective neural activity in the early visual and cortex subcortical nuclei including the lateral geniculate nucleus between AR training and patching for the treatment of adults with unilateral amblyopia.

Read the detailed description

Patching the fellow eye (FE) is typically the first line of amblyopia therapy. Patching treatment has been thought to be effective only when started before the age of eight and might bring limited benifits for adults who have decreased visual cortex plasticity (Bhola et al., 2006). However, recent animal and human studies have demonstrated that visual cortex plasticity and visual functions can be enhanced later in life (Kind et al., 2002; Pineles et al., 2020), paving the way for new strategies for amblyopia treatment.

Dichoptic/binocular digital therapy has been developed with hope to improve visual functions in amblyopia post the critical period. However, no widely accepted binocular treatments with superiority to patching is available in adults with unilateral amblyopia (Pineles et al., 2020; Oscar et al., 2023). Here, we designed an innovative binocular therapy using augmented reality (AR) training, based on neural deficits in amblyopia, in order to achieve better outcomes.

Selective deficits were found in the parvocellular pathway (P pathway) compared to the magnocellular pathway (M pathway) in the monocular processing of visual information in the amblyopic eye (AE) (Wen et al., 2021). In addition to monocular deficits, imbalanced binocular suppression may also play important roles in the visual deficits of amblyopia as suggested by clinical evidence (DeSantis, 2014; Von Noorden, 1996) and psychophysical studies (Baker et al., 2008; Holopigian et al., 1988; Li et al., 2011; Zhou et al., 2013). Based on the neural deficits in unilateral amblyopia, we first apply the push-pull approach (Xu, He \& Ooi, 2010; Ooi et al., 2013), which was aimed to reduce sensory eye dominance in previous literatures, into the rebalance of functions of M and P pathways in the AE and the rebalance of binocular interaction, to improve the high spatial detail perception of the AE in daily life under binocular viewing condition, as well as binocular functions.

Using AR technique combined with dichoptic device, images are processed differently and dichopticaly presented to each eye of the patients in real time, same in the content but different in contrast, spatial frequency, temporal frequency, and signal-to-noise ratio, allowing them to interact with the surrounding environment in real time during the visual training. We aim to achieve push-pull in monocular M-P pathways in the AE and interocular P-P pathways in the FE and the AE, in order to selectively improve the function of the P pathway in the AE under binocular viewing condition.

The proposed trial will be conducted in one study sites in China. For the AR training group, patients need to perform AR training for 2 hours per day at home. For the patching group, patients need to patch the FE for 2 hours per day at home.

02

Conditions studied

  • Amblyopia Unilateral
  • Amblyopia Functional

Browse trials for

Keywords

  • Adult
  • Augmented reality training
  • Patching
  • Neural deficit
03

In context

Amblyopia

183 studies on the registry are indexed under Amblyopia; 43 are open to participants now.

This study's enrollment of 48 is below the median of 60 across 133 interventional studies indexed under Amblyopia.

Browse Amblyopia studies →

Lead sponsor

Eye & ENT Hospital of Fudan University is the lead sponsor of 121 studies on the registry; 67 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Aged 18-50 years (including 18 years and 50 years);
  2. Best-corrected visual acuity worse than 20/30 but no worse than 20/200 in the amblyopic eye, interocular difference of 2 or more lines, with the better eye within the normal range;
  3. Patients with deprivation amblyopia should have relieved the deprivation factors such as opacification of the ocular media (e.g. cataract, nonclearing vitreous opacity, corneal opacities) or other occlusion of the visual axis (e.g. blepharoptosis).
  4. Normal binocular alignment including strabismic amblyopia with orthotropia after optical refractive correction or surgical correction, or intermittent exotropia within a range of -15 to 0 prism diopters measured by the prism cover test.
  5. Patients should have been applyng optical refractive correction for more than 3 months before enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Organic eye diseases preventing the establishment of good vision (e.g. ptosis, media opacity, nystagmus, paracentral fixation, acute inflammation like keratitis, optic nerve diseases like glaucoma, retinal diseases);
  2. Lesions of the brain preventing the establishment of good vision (e.g. cortical visual impairment);
  3. A history of ocular surgery (except strabismus surgery) affecting vision (e.g. retinal detachment repair);
  4. A history of ocular trauma affecting vision;
  5. Receiving amblyopia therapy (except wearing refractive correction glasses) within 2 weeks before enrollment;
  6. History of epilepsy or mental illness, or cognitive defects;
  7. Currently taking medications or needing to take medications during the study period that may affect vision;
  8. Contraindications to magnetic resonance imaging such as implantable electronic device, metal implants (e.g. metal dentures, craniofacial titanium plates), claustrophobia and pregnancy.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    AR training group

    Dichoptic augmented reality training with dual-pathway (parvocellular pathway and magnocellular pathway) and interocular push-pull paradigms developed based on neural deficits in adults with unilateral amblyopia.

    Device: AR training

  • Active comparator
    Patching group

    Conventional patching therapy.

    Device: Patching

Interventions

  • DeviceAR training

    Dichoptic augmented reality training with dual-pathway (parvocellular pathway and magnocellular pathway) and interocular push-pull paradigms developed based on neural deficits in adults with unilateral amblyopia

  • DevicePatching

    Conventional patching therapy.

06

What researchers measure

Primary outcomes

  1. Change in visual acuity at far

    Best-corrected visual acuity in the amblyopic eye measured at the distance of 2.5 meters using standardized logMAR visual charts.

    Time frame: 1 week, 1month, 3month, 6month

Secondary outcomes

  1. Change in visual acuity at near

    Best-corrected visual acuity in the amblyopic eye measured at the distance of 2.2 meters using the Freiburg Visual Acuity test.

    Time frame: 1 week, 1month, 3month, 6month

  2. Change in visual acuity with single tumbling E

    Best-corrected uncrowded and crowded visual acuity in the amblyopic eye measured at the distance of 30 centimeters.

    Time frame: 1 week, 1month, 3month, 6month

  3. Change in contrast sensitivity

    Contrast sensitivity in each eye measured with forced-choice test under binocular viewing.

    Time frame: 1 week, 1month, 3month, 6month

  4. Change in faxation stability

    Fixation stability in each eye measured with EyeLink 1000.

    Time frame: 1 week, 1month, 3month, 6month

  5. Change in binocular phase combination

    Binocular integration measured with phase combination test .

    Time frame: 1 week, 1month, 3month, 6month

  6. Change in binocular rivalry ratio

    Binocular rivalry ratio measured with binocular rivalty test

    Time frame: 1 week, 1month, 3month, 6month

  7. Change in stereopsis

    Near stereopsis measured with Titmus Fly Stereotest pattern.

    Time frame: 1 week, 1month, 3month, 6month

  8. Change in neural activity corresponding to visual inputs in SSVEP

    Pathway-selective neural activity in the early visual cortex revealed by SSVEP.

    Time frame: 1 week, 1month, 3month, 6month

  9. Change in neural activity corresponding to visual inputs in fMRI

    Pathway-selective neural activity in the early visual cortex and subcortical nuclei including lateral geniculate nucleus revealed by fMRI.

    Time frame: 1 week, 1month, 3month, 6month

07

Study locations

1 site
  • Eye & ENT Hospital of Fudan University
    Shanghai, China
08

References and documents

Publications

  • Ooi TL, Su YR, Natale DM, He ZJ. A push-pull treatment for strengthening the 'lazy eye' in amblyopia. Curr Biol. 2013 Apr 22;23(8):R309-10. doi: 10.1016/j.cub.2013.03.004. PubMed 23618663 ↗
  • Xu JP, He ZJ, Ooi TL. Effectively reducing sensory eye dominance with a push-pull perceptual learning protocol. Curr Biol. 2010 Oct 26;20(20):1864-8. doi: 10.1016/j.cub.2010.09.043. Epub 2010 Oct 14. PubMed 20951044 ↗
  • Zhou J, Huang PC, Hess RF. Interocular suppression in amblyopia for global orientation processing. J Vis. 2013 Apr 22;13(5):19. doi: 10.1167/13.5.19. PubMed 23608341 ↗
  • Li J, Thompson B, Lam CS, Deng D, Chan LY, Maehara G, Woo GC, Yu M, Hess RF. The role of suppression in amblyopia. Invest Ophthalmol Vis Sci. 2011 Jun 13;52(7):4169-76. doi: 10.1167/iovs.11-7233. PubMed 21447685 ↗
  • Holopigian K, Blake R, Greenwald MJ. Clinical suppression and amblyopia. Invest Ophthalmol Vis Sci. 1988 Mar;29(3):444-51. PubMed 3343099 ↗
  • Baker DH, Meese TS, Hess RF. Contrast masking in strabismic amblyopia: attenuation, noise, interocular suppression and binocular summation. Vision Res. 2008 Jul;48(15):1625-40. doi: 10.1016/j.visres.2008.04.017. Epub 2008 Jun 10. PubMed 18547600 ↗
  • Von Noorden GK. Binocular vision and ocular motility. Theory and Management of Strabismus. 1996.
  • DeSantis D. Amblyopia. Pediatr Clin North Am. 2014 Jun;61(3):505-18. doi: 10.1016/j.pcl.2014.03.006. Epub 2014 Apr 14. PubMed 24852148 ↗
  • Wen W, Wang Y, Zhou J, He S, Sun X, Liu H, Zhao C, Zhang P. Loss and enhancement of layer-selective signals in geniculostriate and corticotectal pathways of adult human amblyopia. Cell Rep. 2021 Dec 14;37(11):110117. doi: 10.1016/j.celrep.2021.110117. PubMed 34910903 ↗
  • Cruz OA, Repka MX, Hercinovic A, Cotter SA, Lambert SR, Hutchinson AK, Sprunger DT, Morse CL, Wallace DK; American Academy of Ophthalmology Preferred Practice Pattern Pediatric Ophthalmology/Strabismus Panel. Amblyopia Preferred Practice Pattern. Ophthalmology. 2023 Mar;130(3):P136-P178. doi: 10.1016/j.ophtha.2022.11.003. Epub 2022 Dec 14. No abstract available. PubMed 36526450 ↗
  • Pineles SL, Aakalu VK, Hutchinson AK, Galvin JA, Heidary G, Binenbaum G, VanderVeen DK, Lambert SR. Binocular Treatment of Amblyopia: A Report by the American Academy of Ophthalmology. Ophthalmology. 2020 Feb;127(2):261-272. doi: 10.1016/j.ophtha.2019.08.024. Epub 2019 Oct 13. PubMed 31619356 ↗
  • Kind PC, Mitchell DE, Ahmed B, Blakemore C, Bonhoeffer T, Sengpiel F. Correlated binocular activity guides recovery from monocular deprivation. Nature. 2002 Mar 28;416(6879):430-3. doi: 10.1038/416430a. PubMed 11919632 ↗
  • Bhola R, Keech RV, Kutschke P, Pfeifer W, Scott WE. Recurrence of amblyopia after occlusion therapy. Ophthalmology. 2006 Nov;113(11):2097-100. doi: 10.1016/j.ophtha.2006.04.034. PubMed 17074568 ↗

Individual participant data

Plan to share: No — We concerns about patient privacy issues and it's better to protect the publication potential.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06704737
Lead sponsor
Eye & ENT Hospital of Fudan University
Responsible party
Sponsor
First posted
Nov 26, 2024
Start date
Feb 25, 2023
Primary completion
Dec 20, 2024 (estimated)
Completion
Dec 20, 2024 (estimated)
Last update
Nov 26, 2024

Study contacts

Wen Wen, MD, PhD
study chair · Eye & ENT Hospital of Fudan University, Shanghai, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion